Xencor, Inc Income Taxes Receivable, Current
Xencor, Inc (XNCR) had Income Taxes Receivable, Current of $804.00 thousand as of 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Notes › Nontrade Receivables
us-gaap:IncomeTaxesReceivable · last filed 2021-02-24
- 2020-06-30: Income Taxes Receivable, Current $804.00K.
- 2020-03-31: Income Taxes Receivable, Current $904.00K.
- 2019-12-31: Income Taxes Receivable, Current $502.00K.
- 2019-09-30: Income Taxes Receivable, Current $402.00K.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2020-06-30 | $804.00K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $904.00K 10-Q · filed 2020-05-08 |
| 2019-12-31 | $502.00K 10-K · filed 2021-02-24 |
| 2019-09-30 | $402.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $402.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $1.21M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $804.00K 10-K · filed 2020-02-25 |
| 2018-09-30 | $762.00K 10-Q · filed 2018-11-05 |
| 2018-06-30 | $762.00K 10-Q · filed 2018-08-07 |
| 2018-03-31 | $762.00K 10-Q · filed 2018-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |